Evidence map›Paper›PMID 33817108›Full record

ArticleOpen life sciences2018

TUFT1 Promotes Osteosarcoma Cell Proliferation and Predicts Poor Prognosis in Osteosarcoma Patients.

Yao-Ping Yu, Jian-Guo He, Ping Li, Ning-Hui Qiu, Li-Jun Wang, Hui Feng

Abstract read
In one paragraph

Article in Open life sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Tuftelin and HIFs expression in osteogenesis.Histochemistry and cell biology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yao-Ping YuDepartment of Pain, Ningbo Rehabilitation hospital, 502 sangtian Road, Ning Bo, Zhe Jiang, 315040, China.
Jian-Guo HeDepartment of Pain, Ningbo Rehabilitation hospital, 502 sangtian Road, Ning Bo, Zhe Jiang, 315040, China.
Ping LiDepartment of Pain, Ningbo Rehabilitation hospital, 502 sangtian Road, Ning Bo, Zhe Jiang, 315040, China.
Ning-Hui QiuDepartment of Pain, Ningbo Rehabilitation hospital, 502 sangtian Road, Ning Bo, Zhe Jiang, 315040, China.
Li-Jun WangDepartment of Pain, Ningbo Rehabilitation hospital, 502 sangtian Road, Ning Bo, Zhe Jiang, 315040, China.
Hui FengDepartment of Pain, Ningbo Rehabilitation hospital, 502 sangtian Road, Ning Bo, Zhe Jiang, 315040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study is aimed at exploring the role of TUFT1 in osteosarcomas.

methodsWe investigated the expression of TUFT1 in osteosarcoma cell lines and explored the correlation between TUFT1 expression and prognosis in osteosarcoma patients based on the expression data downloaded from Gene Expression Omnibus (GEO) website. The effects of TUFT1 on osteosarcoma cell proliferation, migration and invasion were investigated by silencing TUFT1 in osteosarcoma MG63 cell line. Finally, western blot was performed to determine the expression changes of MAPK signaling pathway related proteins after silencing TUFT1.

resultsWe found that the expression of TUFT1 was significantly up-regulated in osteosarcoma cell lines compared with the normal control. Using Kaplan-Meier analysis, we identified that high TUFT1 expression was positively correlated with poor prognosis in osteosarcoma patients. Furthermore, knockdown of TUFT1 remarkably inhibited MG63 cell proliferation, migration and invasion. Using western blot analysis, we found that the phosphorylation levels of MEK and ERK were reduced obviously in MG63 cells after silencing TUFT1 (p<0.01).

conclusionsOur results demonstrated that TUFT1 plays a promoting role in MG63 cell proliferation and metastasis and has the potential to be a predictor as well as a therapeutic target for osteosarcoma patients.

Indexed as

MAPK signaling pathwaymigrationOsteosarcomaproliferationTuftelin

Identifiers

PMID33817108
PMCPMC7874716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.